“My doctor prescribed a higher dose of GLIVEC as the next step. I’m relieved to know we can continue fighting this cancer.”

When patients with advanced KIT+ GIST experience progression, they need your help to understand their choices:

  • Treatment options do exist, and tumour control may still be possible1-3*
  • After progression, dose escalation with GLIVEC is the recommended next step1,4
  • Patients who tolerated the 400-mg dose prior to dose escalation were less likely to require dose reductions at the 800-mg level than patients initiated at the higher dose3

Models are used for illustrative purposes only throughout the site. Patient quotes are intended for guidance only and do not reflect actual patient testimonials.

*Tumour control is defined as complete response, partial response, or stable disease.

*Tumour control is defined as complete response, partial response, or stable disease.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2016. © National Comprehensive Cancer Network, Inc. 2016. All rights reserved. Accessed September 21, 2016. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2. Glivec® (imatinib) summary of product characteristics. Dublin, Ireland: Novartis Europharm Limited. 3. Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008;44(4):501-509. 4. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(suppl 3):ii21-ii-26.